Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn ' s Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn ' s
Researchers evaluated results of seven major studies to compare efficacy and safety of the two agents in Crohn ' s disease and ulcerative colitis.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news
More News: Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Remicade | Study | Ulcerative Colitis